Arecor Annouce Headline Results from Phase 1 Trial of Ultra-Rapid Acting Insulin Candidate

Cambridge, UK – Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces headline results from the second Phase I clinical trial of its ultra-rapid acting insulin, AT247, which support its potential to facilitate a fully closed loop artificial pancreas.

In summary:

• AT247 delivers significantly accelerated insulin absorption and early exposure (PK profile) compared with NovoLog® and Fiasp®, meeting co-primary endpoint
• AT247 delivers a statistically significant superior glucose lowering effect compared with NovoLog® supporting the accelerated absorption and early exposure PK profile
• AT247 demonstrated a similar PD profile to Fiasp®. The statistically superior co-primary endpoint was not met
• AT247 shown to be safe and efficacious when delivered by continuous subcutaneous (SC) infusion
• Further supports potential to enable more effective disease management for people with Type I diabetes via fully automated closed loop insulin pump delivery (artificial pancreas)

For full information click here.